[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
About the Journal
Editorial Board
Keywords
For Authors::
Aims and Scope
Call for Papers
Submission Instructions
For Reviewers::
Referee page
Subscription::
Subscription Form
News & Events::
Journal News
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE
Volume 23, Issue 3 (7-2025)                   Int J Radiat Res 2025, 23(3): 829-831 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hou H, Huang Q, Su X, Zhang G, Zhang M. 68-Ga-FAPI PET/CT imaging provides better detection of hepatocellular carcinoma recurrence compared with 18-F-FDG: a case report. Int J Radiat Res 2025; 23 (3) :829-831
URL: http://ijrr.com/article-1-6686-en.html
68-Ga-FAPI PET/CT imaging provides better detection of hepatocellular carcinoma recurrence compared with 18-F-FDG: a case report
H. Hou , Q. Huang , X. Su , G. Zhang , M. Zhang
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jie Fang Avenue, Wuhan 430030, Hubei, P.R. China , zms75@163.com
Abstract:   (190 Views)
Background: Globally, primary liver cancer is a common tumor and patients generally have a poor prognosis. Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. In most cases, the diagnosis of HCC relies on imaging. Case presentation: This study reports on a male patient diagnosed with primary HCC who went into remission after hepatectomy, chemotherapy, and splenic embolization. In the 4th year of follow-up, elevated alpha-fetoprotein was detected (325 ng/mL). However, neither computed tomography (CT) nor magnetic resonance imaging (MRI) revealed significant abnormalities. To clarify the diagnosis, 2-deoxy-2-18F-fluoro-D-glucose integrated positron emission tomography/computed tomography (18F-FDG-PET/CT) was used for initial diagnosis. However, no significant FDG uptake was seen in multiple nodules of the liver. Further examination was performed using 68Ga-fibroblast activation protein inhibitor positron emission tomography/computed tomography (68Ga-FAPI PET/CT), which showed intense FAPI uptake in multiple lesions in the liver, providing direct evidence for the diagnosis of potential HCC recurrence. Finally, the lesions were completely resected and the diagnosis of hepatocellular carcinoma (HCC) was confirmed. Conclusion: Previous studies have shown that 68Ga-FAPI PET/CT is more sensitive than 18F-FDG for the detection of HCC. This study suggests that 68Ga-FAPI PET/CT is a new option for patients with recurrent HCC who are not sensitive to 18F-FDG.
Keywords: HCC, recurrence, 18-F-FDG PET/CT, 68-Ga-FAPI PET/CT, case report.
Full-Text [PDF 1038 kb]   (87 Downloads)    
Type of Study: Review article | Subject: Radiation Biology
References
1. Sung H, Ferlay J, Siegel RL, et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3): 209-249. [DOI:10.3322/caac.21660]
2. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatol ogy, 51(5): 1820-32. [DOI:10.1002/hep.23594]
3. Center MM and Jemal A (2011) International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev, 20(11): 2362-8. [DOI:10.1158/1055-9965.EPI-11-0643]
4. Anwanwan D, Singh SK, Singh S, et al. (2020) Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873(1): 188314. [DOI:10.1016/j.bbcan.2019.188314]
5. Bruix J and Sherman M (2011) American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 53(3): 1020-2. [DOI:10.1002/hep.24199]
6. European Association for The Study of The Liver; European Organization for Research and Treatment of Cancer. (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 56(4): 908-43. [DOI:10.1016/j.jhep.2011.12.001]
7. Torizuka T, Tamaki N, Inokuma T, et al. (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med, 36(10): 1811-7.
8. Salem N, MacLennan GT, Kuang Y, et al. (2007) Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol, 9(3): 135-43. [DOI:10.1007/s11307-007-0092-5]
9. Lee JD, Yang WI, Park YN, et al. (2005) Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med, 46(10): 1753-9.
10. Rennert J, Grosse J, Einspieler I, et al. (2021) Complementary imaging of ultrasound and PET/CT: A new opportunity? Clin Hemorheol Microcirc, 79(1): 39-54. [DOI:10.3233/CH-219105]
11. Lee YJ, Lee JM, Lee JS, et al. (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology, 275(1): 97-109. [DOI:10.1148/radiol.14140690]
12. Lim JH, Kim CK, Lee WJ, et al. (2000) Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. Am J Roentgenol, 175(3): 693-8. [DOI:10.2214/ajr.175.3.1750693]
13. Roh MS, Jeong JS, Kim YH, et al. (2004) Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology, 51(59): 1315-8.
14. Cook GJ, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med, 26(4): 308-14. [DOI:10.1016/S0001-2998(96)80006-7]
15. Cheng MF, Guo YL, Yen RF, et al. (2018) Clinical utility of FDG PET/CT in patients with autoimmune pancreatitis: a case-control study. Sci Rep, 8(1): 3651. [DOI:10.1038/s41598-018-21996-5]
16. Puré E and Blomberg R (2018) Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene, 37(32): 4343-4357. [DOI:10.1038/s41388-018-0275-3]
17. Brennen WN, Isaacs JT, Denmeade SR (2012) Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther, 11(2): 257-66. [DOI:10.1158/1535-7163.MCT-11-0340]
18. Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epi thelial cancers. Proc Natl Acad Sci USA, 87(18): 7235-9. [DOI:10.1073/pnas.87.18.7235]
19. Shiga K, Hara M, Nagasaki T, et al. (2015) Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel), 7(4): 2443-58. [DOI:10.3390/cancers7040902]
20. Chen X and Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov, 18(2): 99-115. [DOI:10.1038/s41573-018-0004-1]
21. Altekruse SF, Devesa SS, Dickie LA, et al. (2011) Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag, 38(4): 201-5.
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4722